Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01177527 | Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | active not recruiting | — | 656 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03683680 | Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers | recruiting | N/A | 240 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 |
| NCT06068075 | Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD | active not recruiting | N/A | 340 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03122717 | Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03310879 | Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 | recruiting | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03586453 | Osimertinib In EGFR Mutant Lung Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03789110 | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02279004 | A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care | active not recruiting | — | 840 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | not yet recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT00131014 | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies | recruiting | — | 1,500 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04028531 | Understanding Chronic Lymphocytic Leukemia | recruiting | — | 2,750 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07123649 | Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study(I-MAMMO) | recruiting | Phase 2 | 364 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03483012 | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | completed | Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06502483 | PRISM for Depression and Anxiety in Young Adults With Cancer(PRISM) | completed | N/A | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02287428 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | active not recruiting | Phase 1 | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02326974 | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | active not recruiting | Phase 2 | 164 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02816697 | Implementation of a System-level Tobacco Treatment Intervention | completed | N/A | 263 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | recruiting | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06710548 | REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors | recruiting | N/A | 240 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06923397 | Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | recruiting | N/A | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07519200 | Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention(SHARE-MC) | not yet recruiting | N/A | 96 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02129686 | A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients | completed | N/A | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02086175 | A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02873962 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02133625 | A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03060720 | Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy | active not recruiting | — | 271 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07499999 | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer(BabyTEARS) | not yet recruiting | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03236428 | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04541654 | Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress(LiFT_UP) | recruiting | — | 1,500 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01783587 | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | active not recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03601923 | Niraparib in Patients With Pancreatic Cancer | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04930783 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | active not recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02852655 | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | active not recruiting | Phase 1 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07442578 | Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial(PULSE) | active not recruiting | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03875716 | Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma | recruiting | N/A | 111 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06945120 | ACT Lung Health Intervention: Phase Two | recruiting | N/A | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | active not recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03367247 | BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal | completed | N/A | 121 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03783546 | Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial | completed | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials